Insulin glargine Aventis Pharma

IDrugs

Volumn 3, Issue 9, 2000, Pages 1081-1087

  Jones, Richard ^a  

^a Trinity Cottage   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33747398695     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (104)

1. Endocrine drugs. DRUG NEWS PERSPECT 1995 8 1 49
2. Efficacy of HOE-901 following subcutaneous injection for four days in type I diabetic subjects. Talaulicar M, Willms B, Rosskamp R DIABETOLOGIA 1994 37 Suppl 1 Abs 169
3. Comparison of the human insulin analogs HOE 901 and ASP(B10): Characteristics of receptor binding, activation and tyrosine phosphorylation of different substrate proteins. Berti L, Bossenmaier B, Kellerer M, Seffer E, Seipke G, Haering H DIABETOLOGIA 1995 38 Suppl. 1 A191
4. Growth promoting and metabolic activity of the insulin analogue Hoe 901 in muscle cells. Eckel J, Kolter T, Baehr M, Laemmerhirt H, Spelleken M, Seipke G DIABETOLOGIA 1995 38 Suppl 1 A4
5. HOE 901, a new insulin analogue, for substitution of basal insulin requirement in type I diabetes. Talaulicar M, Willms B, Rosskamp R DIABETES UND STOFF 1996 5 1 3-6
6. HMR refines development strategy. SCRIP 1996 2129 15
7. HMR sets development priorities. SCRIP 1996 2166 10
8. HMR steps up German production. SCRIP 1998 2310 9
9. Hoechst-Stripped to its core. Cantle J, Dyson J ANALYST REPORT 1997 September
10. HMR's hirudin approved in US. SCRIP 1998 2317 13
11. Growth promoting and metabolic activity of the human Insulin analogue (Gly(A21), Arg(B31), Arg(B32) insulin (HOE 901) in muscle cells. Bahr M, Kolter T, Seipke G, Eckel J EUR J PHARMACOL 1997 320 2-3 259-266
12. Hoechst AG ANNUAL REPORT 1997 December 31
13. Hoechst Marion Roussel AG ANNUAL REPORT 1997 December 31
14. Intensive treatment of type 1 diabetes. Hirsch IB MED CLIN NORTH AM 1998 82 4 689-719
15. The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring HU HORM METAB RES 1998 30 3 123-129
16. The absorption of HOE-901 in healthy subjects. Owens D, Luzio S, Tinbergen J, Kurzhals R DIABETOLOGIA 1998 41 Suppl 1 A245
17. A new long-acting insulin (HOE901) demonstrates less nocturnal hypoglycaemia when compared with protamine insulin in a clinical trial. Matthews DR, Pfeiffer C DIABETOLOGIA 1998 41 Suppl 1 A245
18. Efficacy and safety of HOE 901 in patients with type 1 diabetes: A four-week randomised, NPH insulin-controlled trial. Pieber TR, EugeneJolchine I, Derobert E DIABETOLOGIA 1998 41 Suppl 1 A49
19. IGF-I receptor-medicated signalling of the human insulin analogue HOE 901. Liu LS, Koenen M, Seipke G, Eckel J DIABETOLOGIA 1997 40 Suppl 1 A355
20. Characteristics of receptor binding, activation and tyrosine phosphorylation of different substrate proteins. Berti L, Bossenmaier B, Kellerer M, seffer E, Seipke G, Haering H DIABETOLOGIA 1995 38 Suppl 1 A191
21. Growth promoting and metabolic activity of the insulin anaglogue Hoe 901 in muscle cells. Eckel J, Kolter T, Baher M, Laemmerhirt H DIABETOLOGIA 1995 38 Suppl 1 A4
22. Efficacy of HOE 901 following subcutaneous injection for four days in type I diabetic subjects. Talaulicar M, Willms B, Rosskamp R DIABETOLOGIA 1994 37 Suppl 1 A169
23. Comparison of the pharmacokinetics/dynamics of Gly(A21)-Arg(B31, B32)-human-insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglycaemic clamp tehcnique. Dreyer M, Pein M, Schmidt C, Heidtmann B, Schluenzen M, Rosskamp R DIABETOLOGIA 1994 37 Suppl 1 A78
24. BT Alex Brown: Rhône Poulenc/Hoechst BT Alex Brown ANALYST REPORT 1999 January 13
25. Lehman Brothers: Healthcare Global: PharmaPipelines - Volume 1 of 2. Lehman Brothers ANALYST REPORT 1999 February
26. Insulin glargine: the first clinically useful extended-acting insulin in half a century. Home P EXP OPIN INVEST DRUGS 1999 8 3 307-314
27. Efficacy and safety of HOE-901 in patients with Type I diabetes: a four week randomized, NPH insulin controlled trial. Pieber T, Eugene Jolchine I, Derobert E DIABETES 1998 47 1 A62
28. Efficacy and safety of HOE-901 in patients with Type 1 DM: a four week randomized, NPH insulin controlled trial. Rosenstock J, Park G, Zimmerman J DIABETES 1998 47 1 A92
29. Long-acting biosynthetic insulin submitted for regulatory approval in US and Europe. Hoechst Marion Roussel Inc PRESS RELEASE 1999 April 23
30. Hoechst Marion Roussel announces first quarter results. Hoechst Marion Roussel AG PRESS RELEASE 1999 April 29
31. Drug Innovation & Approval Magazine. Hoechst Marion Roussel AG COMPANY BROCHURE 1998 December 1
32. Hoechst Marion Roussel announces second quarter results. Hoechst Marion Roussel AG PRESS RELEASE 1998 August 19
33. Efficacy and safety of HOE 901 (Insulin glargine) in subjects with type 2 DM: A 28-week randomized, NPH insulin-controlled trial. Rosenstock J, Schwartz S, Clark C, Edwards M, Donley D ANN MEET AM DIABETES ASSOC 1999 59 Abs 0432
34. Pharmacokinetics and dynamics of s.c. injection of the long-acting insulin glargine (HOE901) in T1DM. Lepore M, Kurzhals R, Pampanelli S, Bolli GB ANN MEET AM DIABETES ASSOC 1999 59 Abs 0416
35. Time-action profile of the long-acting insulin analogue HOE901. Linkeschowa R, Heise T, Rave K, Hompesch B, Sedlack M, Heinemann L ANN MEET AM DIABETES ASSOC 1999 59 Abs 0417
36. Efficacy and safety of insulin glargine in subjects with type 1 diabetes: A 28 week randomized, NPH insulin-controlled trial. Ratner RE, Hirsch IB, Mecca TE, Wilson CA ANN MEET AM DIABETES ASSOC 1999 59 Abs 0516
37. Treatment satisfaction and psychological well-being in patients with type 1 diabetes, treated with a new long-acting insulin insulin glargine. Witthaus E, Bradley C, Stewart J ANN MEET AM DIABETES ASSOC 1999 59 Abs 1547
38. Insulin glargine clinical studies presented at ADA conference. Hoechst Marion Roussel Inc PRESS RELEASE 1999 June 21
39. ABN AMRO: Pan-Europe Pharmaceuticals: Pan-European Pharmaceutical Review. ABN AMRO ANALYST REPORT 1999 April
40. American Diabetes Association-59th Annual Meeting (Part II) San Diego, CA, USA. IDDB MEETING REPORT 1999 June 17-22
41. Time-action profile of the long-acting insulin analogue HOE901. Linkschowa R, Heise T, Rave K, Hompesch B, Sedlack M, Heinemann L ANN MEET AM DIABETES ASSOC 1999 59 0417
42. Efficacy and safety of HOE 901 (insulin glargine) in subjects with Type2 DM: A 28-week randomized, NPH insulin-controlled trial. Rosenstock J, Schwartz S, Clark C, Edwards M, Donley D ANN MEET AM DIABETES ASSOC 1999 59 0432
43. Comparison of the sc absorption of HOE 901 and NPH human insulin type 2 diabetic subjects. Luzio SD, Owens D, Evans M, Ogunku A, Beck P, Kurzhals R ANN MEET AM DIABETES ASSOC 1999 59 0480
44. Hoechst AG ANNUAL REPORT 1998 December 31
45. Lehman Brothers: Healthcare UK & Europe: Pharmabulletin. Lehman Brothers ANALYST REPORT 1999 May 17
46. Hoechst Marion Roussel Amaryl sales reach $62 million in second quarter. FDC REPORTS PINK SHEET 1999 61 32 20
47. Hoechst Marion Roussel AG ANNUAL REPORT 1998 December 31
48. [Diabetes mellitus: New drugs for diabetic patients]. Diabetes mellitus: Neue Arzneimittel für Diabetiker. Menzel R, Kerner W, Bruns W DTSCH APOTH ZTG 1999 139 30 31-34
49. Binding of phenol to R6 insulin hexamers. Berchtold H, Hilgenfeld R BIOPOLYMERS 1999 51 2 165-172
50. Long-acting insulin analogs. Rosskamp RH, Park G DIABETES CARE 1999 22 2 B109-2 B113
51. New approaches to the treatment of diabetes. Kramer, Werner EXP CLIN ENDOCRINOLOGY DIABETES 1999 107 Suppl 2 S52-S61
52. Basal insulin glargine (HOE-901) in type II diabetes: A 28 week, NPH controlled trial. Rosenstock J, Schwartz S, Clark C, Edwards M, Donley D DIABETOLOGIA 1999 42 Suppl 1 Abs 61
53. Pharmacokinetics and dynamics of s.c. injection of the long-acting Insulin glargine (HOE 901) in TIDM. Lepore M, Kurzhals R, Pampanelli S, Fanelli CG, Bolli GB DIABETOLOGIA 1999 42 Suppl 1 Abs 877
54. Efficacy and safety of insulin glargine in type I diabetes: a 28 week randomised, NPH-controlled trial. Ratner RE, Hirsch IB, Mecca TE, Wilson CA DIABETOLOGIA 1999 42 Suppl 1 Abs 878
55. Characterization of glucose turnover of insulin glargine in comparison with regular human insulin in healthy male subjects. Mohideen P, Mudaliar S, Deutsch R, Ciraldi T, Armstrong D, Kin B, Morrill B, Sha H, Henry R DIABETOLOGIA 1999 42 Suppl 1 Abs 879
56. Time-action profile of the long-acting insulin analogue HOE901. Linkschowa R, Heise T, Rave K, Hompesch B, Heinemann L DIABETOLOGIA 1999 42 Suppl 1 Abs 880
57. A comparison of the pharmacodynamics (glucose lowering effect) of intravenous Hoe 901 and regular insulin using the euglycaemic clamp technique. Meyer BH, Scholtz HE, Nierkerk N van, Rosenkranz B DIABETOLOGIA 1999 42 Suppl 1 Abs 881
58. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique. Scholtz HE, Nierkerk N van, Meyer BH, Rosenkrantz B DIABETOLOGIA 1999 42 Suppl 1 Abs 882
59. Insulin glargine (HOE 901) lowers fasting blood glucose in children with Type I diabetes mellitus without increasing the risk of hypoglycaemia. Schoenle E DIABETOLOGIA 1999 42 Suppl 1 Abs 883
60. HOE 901 (insulin glargine) improves satisfaction with intensified insulin treatment for Type I diabetes. Witthaus E, Bradley C, Stewart J DIABETOLOGIA 1999 42 Suppl 1 Abs 884
61. Pipeline products, phase I, II, III. Aventis Pharma AG COMPANY WORLD WIDE WEB SITE 1999 December 23
62. Lehman Brothers: A Guide to Product Submissions and Approvals in 2000. Lehman Brothers ANALYST REPORT 2000 January 13
63. Aventis: Innovative, collaborative, competitive. Our challenge is life. Aventis SA COMPANY BROCHURE 2000 January
64. Insulin analogues and their potential in the management of diabetes mellitus. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA DIABETOLOGIA 1999 42 10 1151-1167
65. New developments in the treatment of type 1 diabetes mellitus. Haak T EXP CLIN ENDOCRINOLOGY DIABETES 1999 107 Suppl 3 S108-S113
66. Aventis targets 26% annual Rx growth until 2004, with 40% sales in the US. FDC REPORTS PINK SHEET 2000 62 13 14-15
67. Aventis Pharmaceuticals' Lantus (insulin glargine [rDNA origin] injection) approved by FDA for treatment of diabetes. Aventis Pharmaceuticals PRESS RELEASE 2000 April 24
68. A comparison of the pharmacodynamics (glucose lowering effect) of intravenous HOE901 and regular insulin using the euglycaemic clamp technique. Scholtz HE, Pretorius SG, Van Niekerk N, Comm M, Rosenkranz B CLIN PHARMACOL THER 2000 67 2 PII-34
69. An assesment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique. Scholtz HE, Pretorius SG, Wessels DH, Meyer BH, Van Niekerk N, Comm M, Rosenkranz B CLIN PHARMACOL THER 2000 67 2 PII-36
70. Novo Nordisk files lawsuit against Aventis for patent infringement. Novo Nordisk A/S PRESS RELEASE 2000 April 27
71. Pharma pipelines. Lehman Brothers ANALYST REPORT 2000 5 April
72. New insulin presentations. Wroe C PRACTICAL DIABETES INT 1999 16 8 264-265
73. Long acting insulin analogues: can they provide a basal insulin level? Pieber TR J PEDIATR ENDOCRINOL METAB 1999 12 Suppl 3745-750
74. Genetically engineered insulin analogs: Diabetes in the new millenium. Vajo Z, Duckworth C PHARMACOL REV 2000 52 1 1-9
75. [What is new concerning diabetes?]. Was gibt es neues in sachen Diabetes? DTSCH APOTH ZTG 2000 140 12 69-73
76. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Pieber TR, Eugene Jolchine I, Derobert E DIABETES CARE 2000 23 2 157-162
77. Insulin glargine. Gillies PS, Figgitt DP, Lamb HM DRUGS 2000 59 2 253-260
78. Insulin glargine. Viewpoints. Riddle MC, Home PD DRUGS 2000 59 2 261-262
79. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen [2]. Mohn A, Strang S, Wemicke-Panten K, Lang AM, Edge JA, Dunger DB DIABETES CARE 2000 23 4 557-559
80. European Society of Clinical Pharmacy-Spring Conference on Clinical Pharmacy: Clinical Pharmacy Skills for the New Therapeutic Horizons, Reykjavik, Iceland. Natsch S IDDB MEETING REPORT 2000 May 10-13
81. Lehman Brothers-Pharmabulletin. ANALYST REPORT 2000 May 10
82. Aventis Pharmaceuticals. Morgan Stanley Dean Witter ANALYST REPORT 2000 February 22
83. Aventis Pharmaceuticals. ANALYST REPORT 2000 March 17
84. Aventis Pharmaceuticals. CDC BOURSE ANALYST REPORT 2000 April 4
85. Aventis Pharmaceuticals. BNP Equities ANALYST REPORT 2000 April 17
86. Pharmokinetics and dynamics of s.c injection of insulin glargine, NPH, and ultralente in T1DM: comparison with CSII. Lepore M, Pampanelli S, Fanelli CG, Porcellati F, Brunetti P, Bolli GB DIABETES 2000 49 Suppl 1 Abs 36-OR
87. Comparsion of insulin glargine (HOE901) vs NPH insulin during 1 year of insulin combination therapy in type 2 diabetes. Yki-Jarvinen H, Dressier A, Kaziemen M DIABETES 2000 49 Suppl 1 Abs 529-P
88. Time action profile of insulin glargine (HOE901) in Japanese volunteers. Rave K, Heise T, Heineman L DIABETES 2000 49 Suppl 1 Abs 1523-PO
89. Effects of insulin glargine on hypoglycemia awareness and counteregulation. Askari H, Lehner LL, Dagogojack S DIABETES 2000 49 Suppl 1 Abs 1735-PO
90. Effect of glargine on glucose disposal and lipolysis in healthy diabetic subjects. Dagago-Jack S, Askari H, Lehner LL DIABETES 2000 49 Suppl 1 Abs 1737-PO
91. Study finds that Lantus (insulin glargine [rDNA origin] injection) mimicks 24 h basal control of CSII versus NPH and ultralente. Avenus Pharmaceutical PRESS RELEASE 2000 June 09
92. First Aventis Pharma R&D days in London and New York: Aventis Pharma: strong pipeline fuels continued growth. Aventis Pharma AG PRESS RELEASE 2000 May 18
93. Aventis Pharma obtains European Union approval for Lantus once daily, basal insulin analog for the treatment of diabetes; first peakless insulin analogue with 24 hour duration of action receives marketing authorization. Aventis Pharma AG PRESS RELEASE 2000 June 14
94. Annual report 1999 in brief-Aventis SA. Aventis SA ANNUAL REPORT 2000 April 30
95. Summary of the American Diabetes Association 60th Scientific Sessions San Antonio, TX, USA. Worker C IDDB MEETING REPORT 2000 June 9-13
96. New drugs approved by the FDA; New dosage forms and indications; Agents pending FDA approval; Major labeling changes. Baker DE HOSP PHARM 2000 35 6 639-650
97. Advances in the treatment of diabetes mellitus in the elderley: development of insulin analogues. Hoogwerf BJ, Mehta A, Reddy S DRUGS AGING 1996 9 6 438-448
98. Aventis reports life science sales figures for the first half of 2000. Aventis SA PRESS RELEASE 2000 July 28
99. ENDO 2000: 82nd Annual Meeting of The Endocrine Society (Part III), Therapies to Combat the Worldwide Epidemic of Obesity-Related Type II Diabetes, Toronto, Canada. IDDB MEETING REPORT 2000 June 21-24
100. Future - The Aventis magazine: 1/2000. Aventis SA COMPANY BROCHURE 2000 April 30
101. Aventis Pharma R&D Day presentations, May 2000: late-stage pipeline. Aventis Pharma AG COMPANY BROCHURE 2000 May 30
102. Aventis Pharma R&D Day presentations, May 2000: early-stage pipeline. Aventis Pharma AG COMPANY BROCHURE 2000 May 30
103. Aventis SA ANNUAL REPORT 1999 December 31
104. Half-year life science earnings per share increase 54 percent before exceptionals Aventis on track to achieve integration and synergy goals Aventis SA PRESS RELEASE 2000 August 30